Esperite N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 aug 2014 - 08:52
Statutaire naam
Esperite N.V.
Titel
Esperite N.V. implements innovative growth and expansion strategy with already positive EBITDA.
Bericht
Implementation of first three business units completed, launch of Genoma will drive the Group to the next level before the end of the year.
Esperite NV (Euronext.: ESP, 'Esperite' or 'the Group'), the European leader in stem cells cryopreservation, now entering the fields of predictive medicine and translational regenerative medicine R&D, has published its financial results for the six months which ended on June 30, 2014.
Datum laatste update: 08 februari 2025